Results 31 to 40 of about 1,546 (109)

Structural Basis of M3 Muscarinic Receptor Dimer/Oligomer Formation [PDF]

open access: yesJournal of Biological Chemistry, 2011
Class A G protein-coupled receptors (GPCRs) are known to form dimers and/or oligomeric arrays in vitro and in vivo. These complexes are thought to play important roles in modulating class A GPCR function. Many studies suggest that residues located on the "outer" (lipid-facing) surface of the transmembrane (TM) receptor core are critically involved in ...
Sara M, McMillin   +4 more
openaire   +2 more sources

Novel Insights into M3 Muscarinic Acetylcholine Receptor Physiology and Structure [PDF]

open access: yesJournal of Molecular Neuroscience, 2013
Recent studies with M3 muscarinic acetylcholine receptor (M3R) mutant mice suggest that drugs selectively targeting this receptor subtype may prove useful for the treatment of various pathophysiological conditions. Moreover, the use of M3R-based designer G protein-coupled receptors (GPCRs) has provided novel insights into how Gq-coupled GPCRs can ...
Andrew C, Kruse   +4 more
openaire   +2 more sources

The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner

open access: yes, 2010
Degeneration of the cholinergic system is considered to be the underlying pathology that results in the cognitive deficit in Alzheimer's disease. This pathology is thought to be linked to a loss of signaling through the cholinergic M1-muscarinic receptor
Pawlak, Robert   +39 more
core   +1 more source

Antagonist binding profile of the split chimeric muscarinic m2-trunc/m3-tail receptor

open access: yes, 1998
Recent evidence suggests that G-protein-coupled receptors can behave as multiple subunit receptors, and can be split into parts, maintaining their binding ability.
MINARINI A   +14 more
core   +1 more source

Physiological functions of muscarinic receptor M3 [PDF]

open access: yes
Muscarinic receptors belong to the family of G-protein coupled receptors. G-proteins are heterotrimeric GTP-binding proteins that transfer signals from receptors to effectors. Effectors change levels of second messengers in the cell.
Urbánková, Anna
core   +1 more source

Management of an uncommon complication using botulinum toxin type A following prosthetic laryngoplasty

open access: yesEquine Veterinary Education, Volume 38, Issue 7, Page e406-e411, July 2026.
Summary An uncommon complication following prosthetic laryngoplasty was reported in a 4‐year‐old Andalusian mare. The mare was presented with a previously diagnosed left‐sided recurrent laryngeal neuropathy, after initial evaluation the mare underwent ventriculocordectomy and prosthetic laryngoplasty.
J. L. Sanclemente   +2 more
wiley   +1 more source

Don't Sweat It: Cannabinoid CB1 Receptors Reduce Sweating in a Mouse Model

open access: yesThe FASEB Journal, Volume 40, Issue 12, 30 June 2026.
A new galvanic skin response‐based approach offers a simple method for measuring sweating in the paws of mice. This method is used to demonstrate that cannabinoid CB1 receptors reduce baseline sweating in mice, likely via inhibition of sympathetic acetylcholine release via axonal CB1 receptors.
Natalia Murataeva   +3 more
wiley   +1 more source

Rewarding effects of M4 but not M3 muscarinic cholinergic receptor antgonism in the rostromedial tegmental nucleus

open access: yes, 2020
The rostromedial tegmental nucleus (RMTg) receives inputs from the laterodorsal tegmental and pedunculopontine tegmental nuclei, the two principle brainstem cholinergic nuclei.
Scheinman, Sarah B   +3 more
core   +1 more source

Effect of the ligand in the Modeling the 3d structure of the m3 muscarinic receptor [PDF]

open access: yes, 2013
There are still many question open to completely understand the structure-activity relationships of G-protein coupled receptors. Issues like the actual mapping of the binding site of different subtypes, as well as the mechanism of activation are poorly ...
Rasaeifar, Bahareh
core   +1 more source

Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non‐pharmacological strategies

open access: yesAlzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder driven by intersecting pathological processes. Persistent attrition in AD drug‐development pipelines highlights the limited clinical impact of single‐target therapies and has increased interest in multi‐target approaches acting on shared biological hubs.
Humberto Martínez‐Orozco   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy